This page is part of the FHIR Specification (v5.0.0-ballot: FHIR R5 Ballot Preview). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4
Biomedical Research and Regulation Work Group | Maturity Level: N/A | Standards Status: Informative |
Raw JSON (canonical form + also see JSON Format Specification)
Definition for Code SystemResearchStudyPhase
{ "resourceType" : "CodeSystem", "id" : "research-study-phase", "meta" : { "lastUpdated" : "2022-09-07T11:58:29.429+11:00", "profile" : ["http://hl7.org/fhir/StructureDefinition/shareablecodesystem"] }, "text" : { "status" : "generated", "div" : "<div>!-- Snipped for Brevity --></div>" }, "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg", "valueCode" : "brr" }, { "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status", "valueCode" : "draft" }, { "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm", "valueInteger" : 1 }], "url" : "http://terminology.hl7.org/CodeSystem/research-study-phase", "identifier" : [{ "system" : "urn:ietf:rfc:3986", "value" : "urn:oid:2.16.840.1.113883.4.642.4.1247" }], "version" : "5.0.0-ballot", "name" : "ResearchStudyPhase", "title" : "ResearchStudyPhase", "status" : "draft", "experimental" : false, "date" : "2020-12-28T16:55:11+11:00", "publisher" : "HL7 (FHIR Project)", "contact" : [{ "telecom" : [{ "system" : "url", "value" : "http://hl7.org/fhir" }, { "system" : "email", "value" : "fhir@lists.hl7.org" }] }], "description" : "Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.", "caseSensitive" : true, "valueSet" : "http://hl7.org/fhir/ValueSet/research-study-phase", "content" : "complete", "concept" : [{ "code" : "n-a", "display" : "N/A", "definition" : "Trials without phases (for example, studies of devices or behavioral interventions)." }, { "code" : "early-phase-1", "display" : "Early Phase 1", "definition" : "Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0." }, { "code" : "phase-1", "display" : "Phase 1", "definition" : "Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients." }, { "code" : "phase-1-phase-2", "display" : "Phase 1/Phase 2", "definition" : "Trials that are a combination of phases 1 and 2." }, { "code" : "phase-2", "display" : "Phase 2", "definition" : "Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks." }, { "code" : "phase-2-phase-3", "display" : "Phase 2/Phase 3", "definition" : "Trials that are a combination of phases 2 and 3." }, { "code" : "phase-3", "display" : "Phase 3", "definition" : "Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug." }, { "code" : "phase-4", "display" : "Phase 4", "definition" : "Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use." }] }
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.